SGO and Leading Cancer Community Partners Issue Consensus Statement on U.S. Drug Shortages, Urge Policy Action

Today, the Society of Gynecologic Oncology (SGO), in partnership with organizations across the cancer community, released a consensus statement identifying the primary drivers of the persistent drug shortage crisis in the United States and proposing actionable policy solutions to protect access to critical cancer medications.

The statement outlines three priorities that require immediate action to address both the root causes and patient impact of drug shortages:

• Increasing transparency across the drug supply chain;
• Strengthening incentives for manufacturers to invest in high-quality, redundant supply systems; and
• Stabilizing the generic drug market.

Cancer drug shortages continue to pose a serious challenge to delivering safe, timely, and effective care. Over the past five years, hundreds of thousands of cancer patients have experienced disruptions to their treatment plans due to ongoing shortages, often resulting in suboptimal care and outcomes. At the same time, healthcare providers have devoted substantial time and resources to managing these shortages, diverting attention from direct patient care.

This crisis requires comprehensive and coordinated action. Pharmaceutical manufacturers, healthcare providers, and government stakeholders must work together to find sustainable solutions. We urge Congress and the Administration to prioritize targeted policy interventions that address supply chain vulnerabilities and promote a more resilient and reliable drug supply.

The organizations who have issued this statement collectively represent thousands of patients, caregivers, and healthcare professionals nationwide. Together, we are committed to advancing practical, sustainable solutions that ensure a stable supply of essential cancer medications. Ensuring that no patient faces uncertainty regarding the availability of life-saving treatments remains our highest priority.

SIGNATORIES:

Hematology/Oncology Pharmacy Association (HOPA)

American Society of Hematology (ASH)

American Society of Pediatric Hematology/Oncology (ASPHO)

The Andrew McDonough B+ Foundation

Association of American Cancer Institutes (AACI)

Association of Cancer Care Centers (ACCC)

Association of Pediatric Hematology/Oncology Nurses (APHON)

Children’s Brain Tumor Foundation

Children’s Cancer Research Fund

KidneyCAN

Myeloma Research Foundation

National Comprehensive Cancer Network (NCCN)

Network for Collaborative Oncology Development & Advancement (NCODA)

MIB Agents Osteosarcoma

Oncology Nursing Society (ONS)

Ovarian Cancer Research Alliance (OCRA)

Society of Gynecologic Oncology (SGO)